EUVIMEDEUVIMED entdecken
Open Access

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia

Liora M Schultz iD, Anne Eaton iD, Christina Baggott, Jenna Rossoff iD, Snehit Prabhu iD, Amy K Keating iD, Christa Krupski, Holly Pacenta iD, Christine L Philips, Julie-An Talano iD, Amy Moskop iD, Susanne H C Baumeister und 19 weitere

Journal of Clinical Oncology · 10.01.2023 · 41 (2) · 354-363

DOI: 10.1200/jco.22.01076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2023. Verfasst von Liora M Schultz und 30 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse and relapse rates of 14.5% and 28%, respectively, whereas use in the real-world setting showed nonresponse and relapse rates of 15% and 37%. Outcome analyses describing fate after post-CAR nonresponse and relapse remain limited. Here, we aim to establish survival outcomes after nonresponse and both CD19+ and CD19– relapses and explore treatment variables associated with inferior survival. METHODS We conducted a retrospective multi-institutional study of 80 children and young adults with B-cell acute lymphoblastic leukemia experiencing nonresponse (n = 23) or relapse (n = 57) after tisagenlecleucel. We analyze associations between baseline characteristics and these outcomes and establish survival rates and salvage approaches. RESULTS The overall survival (OS) at 12 months was 19% across nonresponders (n = 23; 95% CI, 7 to 50). Ninety-five percent of patients with nonresponse had high preinfusion disease burden. Among 156 morphologic responders, the cumulative incidence of relapse was 37% (95% CI, 30 to 47) at 12 months (CD19+; 21% [15 to 29], CD19–; 16% [11 to 24], median follow-up; 380 days). Across 57 patients experiencing relapse, the OS was 52% (95% CI, 38 to 71) at 12 months after time of relapse. Notably, CD19– relapse was associated with significantly decreased OS as compared with patients who relapsed with conserved CD19 expression (CD19– 12-month OS; 30% [14 to 66], CD19+ 12-month OS; 68% [49 to 92], P = .0068). Inotuzumab, CAR reinfusion, and chemotherapy were used as postrelapse salvage therapy with greatest frequency, yet high variability in treatment sequencing and responses limits efficacy analysis across salvage approaches. CONCLUSION We describe poor survival across patients experiencing nonresponse to tisagenlecleucel. In the post-tisagenlecleucel relapse setting, patients can be salvaged; however, CD19– relapse is distinctly associated with decreased survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansChildYoung AdultAdolescentRetrospective StudiesImmunotherapy, AdoptiveRecurrenceAntigens, CD19Chronic Disease

Substanzen

tisagenlecleucelReceptors, Antigen, T-CellAntigens, CD19

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA.
  • Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN.
  • Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA.
  • Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
  • University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO.
  • Department of Pediatrics, University of Cincinnati, Cincinnati, OH.

ORCID-Profile: Liora M Schultz, Anne Eaton, Jenna Rossoff, Snehit Prabhu, Amy K Keating, Holly Pacenta, Julie-An Talano, Amy Moskop, Muna Qayed, Michelle Hermiston, Prakash Satwani, Vanessa A Fabrizio, Michael Kunicki, Emily Egeler, Yimei Li, Crystal L Mackall, Kevin J Curran, Michael R Verneris, Theodore W Laetsch

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Schultz, L. M., Eaton, A., Baggott, C., Rossoff, J., Prabhu, S., Keating, A. K., Krupski, C., Pacenta, H., Philips, C. L., Talano, J. A., Moskop, A., Baumeister, S. H. C., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Wilcox, R., …, & Stefanski, H. (2023). Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 41(2), 354-363. https://doi.org/10.1200/jco.22.01076

Vancouver

Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, et al. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology. 2023;41(2):354-363. doi:10.1200/jco.22.01076

BibTeX
@article{Schultz2023,
  author = {Schultz, Liora M and Eaton, Anne and Baggott, Christina and Rossoff, Jenna and Prabhu, Snehit and Keating, Amy K and Krupski, Christa and Pacenta, Holly and Philips, Christine L and Talano, Julie-An and Moskop, Amy and Baumeister, Susanne H C and Myers, Gary Douglas and Karras, Nicole A and Brown, Patrick A and Qayed, Muna and Hermiston, Michelle and Satwani, Prakash and Wilcox, Rachel and Rabik, Cara A and Fabrizio, Vanessa A and Chinnabhandar, Vasant and Kunicki, Michael and Mavroukakis, Sharon and Egeler, Emily and Li, Yimei and Mackall, Crystal L and Curran, Kevin J and Verneris, Michael R and Laetsch, Theodore W and Stefanski, Heather},
  title = {Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {2},
  pages = {354--363},
  doi = {10.1200/jco.22.01076}
}
Kostenlos starten →